Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Nasopharyngeal Carcinoma 39Carcinoma, Non-Small-Cell Lung 30Esophageal Squamous Cell Carcinoma 23Carcinoma, Hepatocellular 23Triple Negative Breast Neoplasms 19Breast Neoplasms 18Squamous Cell Carcinoma of Head and Neck 17Advanced Solid Tumor 17Melanoma 15Stomach Neoplasms 14Small Cell Lung Carcinoma 13Colorectal Neoplasms 13Uterine Cervical Neoplasms 12Neoplasms 10Carcinoma, Transitional Cell 10Carcinoma, Renal Cell 10Recurrence 9Head and Neck Neoplasms 8Solid Tumor 7Sarcoma 7Neoplasm Metastasis 7Liver Neoplasms 7Esophageal Neoplasms 6Urinary Bladder Neoplasms 5Rectal Neoplasms 5Advanced Solid Tumors 5Pancreatic Neoplasms 4Nasopharyngeal Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4

Interventions

Cetuximab 2Alpelisib 2toripalimab 1sintilimab 1rocakinogene sifuplasmid 1raltitrexed 1cabozantinib 1VGX-3100 1Radiotherapy, Intensity-Modulated 1Metformin 1MEDI0457 1Fluorouracil 1Cisplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Squamous Cell Cancer × toripalimab × Clear all
NCT04856631 2022-12-19

A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Unknown
88 enrolled
Head & Neck

Head and Neck Squamous Cell Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡